Peer-reviewedLicence not statedJAMA
Ceperognastat in Early Symptomatic Alzheimer Disease
- 1Eli Lilly and Company, Indianapolis, Indiana
Related
- Clinical Meaningfulness of Donanemab in Early Symptomatic Alzheimer Disease
- Mitochondrial bioenergetic signatures differentiate asymptomatic from symptomatic Alzheimer’s disease
- Dysregulation of LINGO1 expression in the SOD1(G93A) mutant mice during symptomatic stages of the disease and early postnatal oligodendrogenesis
- Decoupling of spontaneous and evoked activity in locus coeruleus neurons: early synaptic and ion-channel remodeling in a mouse model of Alzheimer's disease
- Network-level restoration of impaired memory function in early Alzheimer’s disease via GluN2B modulation: insights from a hippocampal CA1–CA3 model
BibTeX
@article{fleisher2026ceperognastat,
title = {{Ceperognastat in Early Symptomatic Alzheimer Disease}},
author = {Adam Fleisher and Leanne M. Munsie and Michele Mancini and Yun‐Ju Cheng and Jiaying Guo and Hugh Norman Nuthall and Diana Otero Svaldi and Vikas Kotari and William Kielbasa and Michael L. Hutton and Mirosław Bryś and Dustin J. Mergott and Mark Mintun and Oskar Hansson},
journal = {JAMA},
year = {2026},
month = jul,
doi = {10.1001/jama.2026.12768},
url = {https://pubmed.ncbi.nlm.nih.gov/42441396/},
}
RIS
TY - JOUR
TI - Ceperognastat in Early Symptomatic Alzheimer Disease
AU - Adam Fleisher
AU - Leanne M. Munsie
AU - Michele Mancini
AU - Yun‐Ju Cheng
AU - Jiaying Guo
AU - Hugh Norman Nuthall
AU - Diana Otero Svaldi
AU - Vikas Kotari
AU - William Kielbasa
AU - Michael L. Hutton
AU - Mirosław Bryś
AU - Dustin J. Mergott
AU - Mark Mintun
AU - Oskar Hansson
PY - 2026
DA - 2026/07/13
JO - JAMA
DO - 10.1001/jama.2026.12768
UR - https://pubmed.ncbi.nlm.nih.gov/42441396/
SN - 0002-9955
SN - 0098-7484
SN - 1538-3598
SN - 2376-8118
ER -